Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uridine Supplementation in HIV Lipoatrophy
NCT00307164Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2006
- Primary completion
- Dec 2008
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of uridine triacetate in HIV-associated lipoatrophy, sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2006; status: completed.
02
Drugs
uridine triacetate
03
Conditions
HIV-associated lipoatrophy
Beyond the preview
Go deeper on NCT00307164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307164.